Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review.
Аннотация
OBJECTIVE
To determine the benefits and harms of therapies used to prevent or treat renal involvement in Henoch-Schönlein purpura.
DESIGN
Systematic review of randomised controlled trials.
SETTING
Secondary and tertiary paediatric and paediatric nephrology services.
SUBJECTS: Ten trials involving 1230 children aged less than 18 years.
MAIN OUTCOME MEASURES: Persistent proteinuria and/or haematuria.
RESULTS
Meta-analyses of four trials showed no significant difference in the risk of persistent kidney disease at 6 months (379 children; relative risk (RR) 0.51, 95% CI 0.24 to 1.11) and 12 months (498 children; RR 1.02, 95% CI 0.40 to 2.62) in children given prednisone for 14-28 days at presentation of Henoch-Schönlein purpura compared with placebo or supportive treatment. In children with severe renal disease, there was no significant difference in the risk of persistent renal disease with cyclophosphamide compared with supportive treatment (one trial; 56 children; RR 1.07, 95% CI 0.65 to 1.78) and with cyclosporin compared with methylprednisolone (one trial; 19 children; RR 0.39; 95% CI 0.14 to 1.06).
CONCLUSIONS
Data from randomised trials for any intervention used to improve renal outcomes in children with Henoch-Schönlein purpura are very sparse except for short-term prednisone, which has not been shown to be effective.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.